Search Results

You are looking at 81 - 90 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Primary Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer in Asia: Unique or Not?

Masaki Shiota

expectancy <10 years was challenged. This study has several limitations. First, the data on diagnosis, therapeutics, and outcome are very limited, and Gleason score, prostate-specific antigen level at diagnosis, detailed clinical stage and modality used for

Full access

Management of Patients With Nonmetastatic Prostate Cancer

Presented by: Julio M. Pow-Sang

, Julio M. Pow-Sang, MD, Chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discussed standard tools for risk stratification, including prostate-specific antigen (PSA), Gleason score, and T stage, and described newer modalities, such as

Full access

Prostate Cancer, Version 1.2014

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead, and Maria Ho

treatment morbidity, and improve quality of life. 4 , 5 The risk-to-benefit ratio of therapy is very different between asymptomatic patients experiencing an increase in prostate-specific antigen (PSA) and patients with symptomatic metastases. However, past

Full access

The Role of Active Surveillance in the Management of Prostate Cancer

Simon D. Fung-Kee-Fung, Sima P. Porten, Maxwell V. Meng, and Michael Kuettel

The recent controversy and debate regarding the use of prostate-specific antigen (PSA) testing to screen for prostate cancer has highlighted critical aspects of prostate cancer management and stimulated reconsideration of how to care for men with

Full access

Impact of an NCCN-Compliant Multidisciplinary Conference on Treatment Decisions for Localized Prostate Cancer

Ahmed A. Hussein, Umar Iqbal, Zhe Jing, Yousuf Ramahi, Holly Houenstein, Stephanie Newman, Blake Peterson, Katarina Krajacic, Adeena Samoni, Bo Xu, Norbert Sule, Gissou Azabdaftari, Eric C. Kauffman, James L. Mohler, Michael Kuettel, and Khurshid A. Guru

urologists, radiation oncologists, pathologists, and patient advocates. Data for all patients were reviewed, including demographics, comorbidity-adjusted life expectancy, prostate-specific antigen (PSA) kinetics, PSA density, NCCN risk group, staging scans

Full access

Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey

Omar Abdel-Rahman

sensitivity analyses. Prostate cancer screening was not evaluated in the current study because current CTFPHC guidelines recommend against routine prostate-specific antigen screening for men with an average risk of prostate cancer. 14 Note that models for

Full access

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

prostate-specific antigen-based screening . J Clin Oncol 2015 ; 33 : 2416 – 2423 . 26056181 10.1200/JCO.2015.61.6532 10. Etzioni R , Gulati R . Recent trends in PSA testing and prostate cancer incidence: a look at context . JAMA Oncol 2016 ; 2

Full access

Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer

Ravi A. Madan, Thomas Schwaab, and James L. Gulley

shown an ability to shrink tumor or decrease prostate-specific antigen (PSA) levels in most patients, in apparent contradiction to the ultimate outcome of 2 phase III studies that showed improved survival. 4 , 6 Closer analysis, however, shows that 2

Full access

Time to Change: Supporting Sexual and Gender Minority People—An Underserved, Understudied Cancer Risk Population

Juno Obedin-Maliver

, noting that prostate examinations are best performed via the neovagina, and discussing how estrogen administration alters prostate-specific antigen (PSA) levels. On a broader scale, altering NCCN Guidelines language for relevance to people of all genders

Full access

New Developments in the Treatment of Castration-Resistant Prostate Cancer

Celestia S. Higano

informed that a decline in prostate-specific antigen (PSA) level is not expected with immunotherapy. Furthermore, as some patients may develop pain after infusion with sipuleucel-T, Dr. Higano encourages baseline imaging and monthly clinical evaluations for